RT Journal Article
SR Electronic
T1 Significance of Pre-treatment Interferon-gamma Release in Patients With Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitors
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6971
OP 6978
DO 10.21873/anticanres.14721
VO 40
IS 12
A1 HIRASHIMA, TOMONORI
A1 KANAI, TOMOHIRO
A1 SUZUKI, HIDEKAZU
A1 YOSHIDA, HIROKO
A1 MATSUSITA, AKANE
A1 KAWASUMI, HIROMI
A1 NASU, SHINGO
A1 TANAKA, AYAKO
A1 MORISHITA, NAOKO
A1 KAWAHARA, KUNIMITSU
A1 TAMURA, YOSHITAKA
A1 OKAMOTO, NORIO
YR 2020
UL http://ar.iiarjournals.org/content/40/12/6971.abstract
AB Background/Aim: We retrospectively investigated the significance of pre-treatment interferon-gamma release (IGR) as a biomarker for predicting the efficacy of immune checkpoint inhibitor treatment (ICI-tx). Patients and Methods: This study included non-small-cell lung cancer patients who received ICI-tx between January 1, 2016 and April 30, 2019. IGR was measured using the positive control of an enzyme-linked immunosorbent assay. We defined the pre-treatment cut-off level of IGR as 10 IU/ml. Results: Fifty-four patients were divided into two groups; those with an IGR ≤10 IU/ml (lower group: LG) (n=15) and those with >10 IU/ml (higher group: HG) (n=39). The time to treatment failure (TTF) in the HG was significantly longer than that in the LG. In multivariate analyses, C-reactive protein and IGR levels were significant risk factors for TTF. Conclusion: Pre-treatment IGR level of >10 IU/ml is recommended to identify those patients who will respond favourably to ICI-tx.